Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.
作者信息
Riaz Rumaisa, Khan Afsheen, Siddiqui Tasmiyah
机构信息
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
出版信息
Rare Tumors. 2023 Jul 31;15:20363613231193566. doi: 10.1177/20363613231193566. eCollection 2023.
Abstract
摘要
相似文献
1
Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.依泊妥单抗-拜斯博（Epkinly）——弥漫性大B细胞淋巴瘤治疗领域的一项重大突破。
Rare Tumors. 2023 Jul 31;15:20363613231193566. doi: 10.1177/20363613231193566. eCollection 2023.
2
Epcoritamab (Epkinly) for diffuse large B-cell lymphoma (DLBCL).用于弥漫性大B细胞淋巴瘤（DLBCL）的艾可瑞妥单抗（Epkinly）
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-e104. doi: 10.58347/tml.2023.1678d.
3
Glofitamab (Columvi) for diffuse large B-cell lymphoma.用于弥漫性大B细胞淋巴瘤的 glofitamab（Columvi）。
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e129-e130. doi: 10.58347/tml.2023.1682b.
4
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.皮下注射依鲁替尼在复发或难治性 B 细胞非霍奇金淋巴瘤患者中的剂量递增：一项开放标签、1/2 期研究。
Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8.
5
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.依帕珠单抗针对 DLBCL、FL 和 MCL 患者的恶性 B 细胞具有强大的抗肿瘤活性，无论先前是否接受过 CD20 单克隆抗体治疗。
Blood Cancer J. 2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6.
6
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.依帕珠单抗，一种新型皮下注射 CD3xCD20 双特异性 T 细胞接合抗体，用于治疗复发/难治性大 B 细胞淋巴瘤：一项 I/II 期试验的剂量扩展。
J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22.
7
Epcoritamab-bysp.
Am J Health Syst Pharm. 2023 Sep 22;80(19):1289-1292. doi: 10.1093/ajhp/zxad146.
8
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.CD3×CD20 双特异性抗体 epcoritamab 在 CLL 中的细胞毒性可通过同时靶向 BTK 或 BCL-2 而增强。
Blood Adv. 2023 Aug 8;7(15):4089-4101. doi: 10.1182/bloodadvances.2022009517.
9
Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas.用于指导依帕珠单抗剂量选择的半机械论生理基于药代动力学/药效学模型：用于 B 细胞淋巴瘤患者。
Clin Pharmacol Ther. 2022 Nov;112(5):1108-1119. doi: 10.1002/cpt.2729. Epub 2022 Sep 27.
10
Epcoritamab is active in large B cell lymphomas.
Nat Rev Clin Oncol. 2023 Mar;20(3):138. doi: 10.1038/s41571-023-00730-9.
引用本文的文献
1
Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report.用依泊妥单抗成功治疗的多次治疗后难治性弥漫性大B细胞淋巴瘤：病例报告
Case Rep Oncol. 2025 Mar 29;18(1):744-750. doi: 10.1159/000545372. eCollection 2025 Jan-Dec.
2
A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy.关于单克隆抗体在癌症治疗中应用的综合综述。
Antibodies (Basel). 2025 Apr 11;14(2):35. doi: 10.3390/antib14020035.
3
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.一年药理学：2023 年美国食品药品监督管理局批准的新药。
Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):2949-2970. doi: 10.1007/s00210-024-03063-1. Epub 2024 Mar 26.
Zotero 插件